Everything below concerns visceral adipose tissue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Amphetamine has a very similar structure and function to the endogenous trace amines, which are naturally occurring neuromodulator molecules produced in the human body and brain. Among this group, the most closely related compounds are phenethylamine, the parent compound of amphetamine, and N-methylphenethylamine, a structural isomer of amphetamine (i.e., it has an identical molecular formula). In humans, phenethylamine is produced directly from L-phenylalanine by the aromatic amino acid decarboxylase (AADC) enzyme, which converts L-DOPA into dopamine as well. In turn, N-methylphenethylamine is metabolized from phenethylamine by phenylethanolamine N-methyltransferase, the same enzyme that metabolizes norepinephrine into epinephrine. Like amphetamine, both phenethylamine and N-methylphenethylamine regulate monoamine neurotransmission via TAAR1; unlike amphetamine, both of these substances are broken down by monoamine oxidase B, and therefore have a shorter half-life than amphetamine.
== Contaminant == A contaminant is a substance present in nature at a level higher than fixed levels or that would not otherwise be there. This may be due to human activity and bioactivity. The term contaminant is often used interchangeably with pollutant, which is a substance that detrimentally impacts the surrounding environment. While a contaminant is sometimes a substance in the environment as a result of human activity, but without harmful effects, it is sometimes the case that toxic or harmful effects from contamination only become apparent at a later date. The "medium" such as soil or organism such as fish affected by the pollutant or contaminant is called a receptor, whilst a sink is a chemical medium or species that retains and interacts with the pollutant such as carbon sink and its effects by microbes.
=== Depression === There is evidence suggesting that activation of the AMPA receptor, downstream activation of mammalian target of rapamycin (mTOR), and upregulation of brain-derived neurotrophic factor (BDNF) are central to the antidepressant effects of certain NMDA receptor antagonists such as ketamine. Blockage of the AMPA receptor nullifies the antidepressant actions of ketamine in rodents. By potentiating the effect of endogenous glutamate at the AMPA receptor, osavampator more directly influences AMPA receptor-mediated transcription. The potential use of osavampator as a non-psychotomimetic antidepressant is cited as reason for its investigation. Initial research found that osavampator, unlike ketamine, did not induce hyperlocomotor responses in rats. However, a later human trial investigating the central nervous system (CNS) stimulatory properties and tolerability of osavampator reported that although the CNS stimulatory properties of the drug were less pronounced than other psychostimulants, osavampator did appear to possess at least some stimulant-like effects. No severe adverse effects were noted in the trial. AMPA receptor agonists are likely not viable for clinical applications as they present a risk of inducing seizures and overexcitation-induced neurotoxicity at doses close to their therapeutic window. Osavampator possesses minimal direct AMPA agonist properties. Osavampator provides a 419-fold safety margin against convulsions relative to therapeutic doses in rats.
=== Novo Nordisk Foundation === On March 1, 2021, Thomsen was appointed CEO of the Novo Nordisk Foundation, a philanthropic organization that funds research in health, life sciences, and sustainability.
Sources: en.wikipedia.org
Each of the United States armed services had its own ICBM development program. The Air Force began ICBM research in 1945 with the MX-774. In 1950, von Braun began testing the Air Force PGM-11 Redstone rocket family at Cape Canaveral. By 1957, a descendant of the Air Force MX-774 received top-priority funding. and evolved into the Atlas-A, the first successful American ICBM. The Atlas made use of a thin stainless steel fuel tank which relied on the internal pressure of the tank for structural integrity, this allowed an overall lighter weight design. WD-40 was developed to prevent rust on the Atlas rockets so that rust protecting paint could be avoided, to further reduce weight. A later variant of the Atlas, the Atlas-D, served as a nuclear ICBM and as the orbital launch vehicle for Project Mercury and the remote-controlled Agena Target Vehicle used in Project Gemini.
Lithium and sodium react with carbon to form acetylides, Li2C2 and Na2C2, which can also be obtained by reaction of the metal with acetylene. Potassium, rubidium, and caesium react with graphite; their atoms are intercalated between the hexagonal graphite layers, forming graphite intercalation compounds of formulae MC60 (dark grey, almost black), MC48 (dark grey, almost black), MC36 (blue), MC24 (steel blue), and MC8 (bronze) (M = K, Rb, or Cs). These compounds are over 200 times more electrically conductive than pure graphite, suggesting that the valence electron of the alkali metal is transferred to the graphite layers (e.g. M+C−8). Upon heating of KC8, the elimination of potassium atoms results in the conversion in sequence to KC24, KC36, KC48 and finally KC60. KC8 is a very strong reducing agent and is pyrophoric and explodes on contact with water. While the larger alkali metals (K, Rb, and Cs) initially form MC8, the smaller ones initially form MC6, and indeed they require reaction of the metals with graphite at high temperatures around 500 °C to form. Apart from this, the alkali metals are such strong reducing agents that they can even reduce buckminsterfullerene to produce solid fullerides MnC60; sodium, potassium, rubidium, and caesium can form fullerides where n = 2, 3, 4, or 6, and rubidium and caesium additionally can achieve n = 1.
== Early business career == Bello entered the Amos Tuck School at Dartmouth College, graduating with an MBA in 1974. While at Tuck he was named an Edward Tuck Scholar. After Tuck, his first business position was in brand management at General Foods, where he worked on Sanka and Maxwell House coffee brands. After an interim experience in athletic footwear as product director for Keds Brand footwear, he moved on to a strategic planning and marketing functions in the Pepsi Cola Division of PepsiCo where he worked on Mountain Dew and the Pepsi Challenge.
The publishing of this list and the subsequent fall-out, banks indiscriminately de-risking MSBs, is referred to as Operation Choke Point. The Financial Crimes Enforcement Network issued a Geographic Targeting Order to combat illegal money laundering in the United States. This means that title insurance companies in the U.S. are required to identify the natural persons behind companies that pay all cash in residential real estate purchases over a particular amount in certain U.S. cities. The Corporate Transparency Act (CTA) is a significant piece of legislation in the United States aimed at combating money laundering and enhancing financial transparency. Enacted as part of the National Defense Authorization Act for Fiscal Year 2021, the CTA mandates that corporations, limited liability companies (LLCs), and similar entities disclose information about their beneficial owners to the Financial Crimes Enforcement Network (FinCEN). This requirement is designed to help authorities identify and track individuals who control or profit from these entities, thereby closing loopholes often exploited for illicit activities. The CTA requires entities to file Beneficial Ownership Information (BOI) reports with FinCEN. These reports must include details such as the names, addresses, dates of birth, and identification numbers of the beneficial owners. By gathering this information, the CTA aims to create a comprehensive database that federal, state, and local law enforcement agencies can access to investigate and prevent financial crimes.
== PSP in wild marine mammals == PSP has been implicated as a possible cause of sea otter mortality and morbidity in Alaska, as one of its primary prey items, the butter clam (Saxidomus gigantea) bioaccumulates saxitoxin as a chemical defense mechanism. In addition, ingestion of saxitoxin-containing mackerel has been implicated in the death of humpback whales. Additional cases where PSP was suspected as the cause of death in Mediterranean monk seals (Monachus monachus) in the Mediterranean Sea have been questioned due to lack of additional testing to rule out other causes of mortality.
Sources: en.wikipedia.org
cytomics The interdisciplinary field that studies cell biology, cytology, and biochemistry at the level of an individual cell by making use of single-cell molecular techniques and advanced microscopy to visualize the interactions of cellular components in vivo.
== Application in human evolution and disease == In the human genome, the frequency and characteristics of de novo mutations have been studied as important contextual factors to our evolution. Compared to the human reference genome, a typical human genome varies at approximately 4.1 to 5.0 million loci, and the majority of this genetic diversity is shared by nearly 0.5% of the population. The typical human genome also contains 40,000 to 200,000 rare variants observed in less than 0.5% of the population that can only have occurred from at least one de novo germline mutation in the history of human evolution. De novo mutations have also been researched as playing a crucial role in the persistence of genetic disease in humans. With recents advancements in next-generation sequencing (NGS), all types of de novo mutations within the genome can be directly studied, the detection of which provides a magnitude of insight toward the causes of both rare and common genetic disorders. Currently, the best estimate of the average human germline SNV mutation rate is 1.18 x 10^-8, with an approximate ~78 novel mutations per generation. The ability to conduct whole genome sequencing of parents and offspring allows for the comparison of mutation rates between generations, narrowing down the origin possibilities of certain genetic disorders.
=== Other Heseltine comments === Heseltine criticised the Coalition's policy on Europe, but he did support the tightening of immigration laws. He also supported George Osborne's Budget measures in 2013 and Iain Duncan Smith's welfare reforms, but showed concerns over the legalisation of same-sex marriage. In June 2013, he voted against Lord Dear's wrecking amendment, thus ratifying the same-sex marriage act.
==== Structural abnormalities ==== Hemoglobin structural variants manifest a change in the structure of the Hb molecule. The majority of hemoglobin variants do not cause disease and are most commonly discovered either incidentally or through newborn screening. Hb variants can usually be detected by protein-based assay methods such as electrophoresis, isoelectric focusing, or high-performance liquid chromatography. Diagnosis is commonly confirmed by DNA sequencing. The hemoglobin structural variants can be broadly classified as follows:
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.